Johnson & Johnson Innovation has announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across pharmaceuticals, medical device and diagnostics and consumer healthcare.
"The future of healthcare will be defined by companies, academic institutions and governments that collaborate to leverage existing strengths, while at the same time think outside current paradigms and experiment with new ways of innovating," said Paul Stoffels, M.D., chief scientific officer, Johnson & Johnson and worldwide chairman, pharmaceuticals. "By being where these new frontiers in science and technology are being forged, our goal is to translate these insights into promising treatments for the future."
Launched more than a year ago, Johnson & Johnson Innovation centers are working globally with life science researchers and entrepreneurs to identify exciting early-stage technologies and translate them into solutions for patients.
The early-stage collaborations announced represent recent R&D alliances facilitated by the Boston, California and London innovation centers and include technologies such as 3-D printing for orthopedic trauma, creating new brown fat for metabolic diseases and advancing novel science in areas of significant unmet medical need such as lymphoma, rheumatoid arthritis, prostate cancer, dementia, Alzheimer's, diabetes and insomnia.
The collaborations include new cancer treatments targeting lymphoma, patient-specific 3D printing for orthopedic needs, advancing progress on Alzheimer's disease and neuroscience, seeking novel approaches to treat diabetes and cardiovascular disease, targeting autoimmune disease, new strategies for skin and oral and respiratory conditions.
J&J Innovation launched the innovation centers last year, establishing four regional hubs to identify scientific opportunities with the potential to advance the development of new healthcare solutions. Through the innovation centers, external innovators have access to a broad range of resources within J&J, including funding, R&D experience and incubation at one of the company's four Janssen Labs facilities. There currently are fully operational offices in Boston, London and California, and a fourth location in Shanghai now houses a small, growing scientific team and will officially open this year to develop collaborations across the Asia Pacific region.